Gas SF6 (Sulfur Hexafluoride)
PreclinicalSmall molecule
Gas SF6 (Sulfur Hexafluoride) is one of 12 small molecule programs targeting Keratoconus. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Keratoconus
#DrugCompanyPhaseTrials
1Neurontin
VViatris Specialty LLC
Approved
Toradol
JJavelin Pharmaceuticals
Approved
Mitosol
UUroGen Pharma Ltd.
Approved
Decadron
AAspen Global Incorporated
Approved
Pred Forte
NovartisPhase 1
Ricrolin+
IIcahn School of Medicine at Mount Sinai
Phase 3
Hypotonic Riboflavin
CCornea and Laser Eye Institute
Phase 3
Neoral
NovartisPreclinical
Riboflavin
CCornea and Laser Eye Institute
Preclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHaEmek Medical Center, Israel